MedTrace Logo

Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block

NCT03874806 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2019-07-15

No results posted yet for this study

Summary

The goals of this study are as follows:

1. to confirm the safe dosing of ropivacaine for the erector spinae plane block
2. develop a pharmacokinetic profile of the erector spinae plane block, which will help demonstrate how quickly and how closely toxic levels are reached when a routine dose of ropivacaine is given for this nerve block
3. assess numbness created by the erector spinae block when routine doses are administered

Conditions

  • Pain, Postoperative
  • Pain, Chest

Interventions

DRUG

Ropivacaine 0.25%-NaCl 0.9% Injectable Solution

0.25% ropivacaine administered through a nerve catheter

DRUG

Ropivacaine 0.2%-NaCl 0.9% Injectable Solution

0.2% ropivacaine administered through a nerve catheter

Sponsors & Collaborators

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Bryant Tran, MD · Virginia Commonwealth University

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-07-01
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03874806 on ClinicalTrials.gov